Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1479-5876

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? ; volume:16 ; number:1 ; day:6 ; month:8 ; year:2018 ; pages:1-6 ; date:12.2018
Journal of translational medicine ; 16, Heft 1 (6.8.2018), 1-6, 12.2018

Creator: Botticelli, Andrea

Contributor: Cerbelli, Bruna
Lionetto, Luana
Zizzari, Ilaria
Salati, Massimiliano
Pisano, Annalinda
Federica, Mazzuca
Simmaco, Maurizio
Nuti, Marianna
Marchetti, Paolo
SpringerLink (Online service)

DOI: 10.1186/s12967-018-1595-3

URN: urn:nbn:de:101:1-2018100622142089181783

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Botticelli, Andrea
Cerbelli, Bruna
Lionetto, Luana
Zizzari, Ilaria
Salati, Massimiliano
Pisano, Annalinda
Federica, Mazzuca
Simmaco, Maurizio
Nuti, Marianna
Marchetti, Paolo
SpringerLink (Online service)

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1

Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1

Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1

Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1

Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1

Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1

Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Related objects

Reset password